Barclays Lowers uniQure (NASDAQ:QURE) Price Target to $25.00

uniQure (NASDAQ:QURE) had its target price dropped by equities researchers at Barclays from $31.00 to $25.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s target price points to a potential upside of 64.69% from the company’s current price.

Other analysts also recently issued research reports about the company. Chardan Capital boosted their price objective on uniQure from $16.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Wolfe Research began coverage on shares of uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. TD Cowen reissued a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Cantor Fitzgerald restated a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.75.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $15.18 on Monday. The stock’s fifty day simple moving average is $20.32 and its 200 day simple moving average is $29.61. The stock has a market capitalization of $949.21 million, a price-to-earnings ratio of -4.40 and a beta of 0.73. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure has a 52-week low of $7.76 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The business had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. As a group, sell-side analysts forecast that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director owned 20,439 shares in the company, valued at $557,575.92. This represents a 23.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christian Klemt sold 12,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the sale, the chief financial officer directly owned 226,581 shares of the company’s stock, valued at $2,052,823.86. This trade represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 81,399 shares of company stock worth $1,527,645. Corporate insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Private Trust Co. NA purchased a new stake in uniQure in the 3rd quarter worth approximately $28,000. Jones Financial Companies Lllp grew its holdings in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of uniQure by 5.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 533 shares in the last quarter. Arizona State Retirement System increased its stake in shares of uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 627 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its holdings in shares of uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after acquiring an additional 650 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Short‑interest data published today is inconsistent/unclear (entries show zero shares and NaN changes), so there’s no reliable public signal of a meaningful new short squeeze or covering pressure at this time.
• Negative Sentiment: Multiple plaintiffs’ law firms have announced or updated securities‑fraud probes and a class action against uniQure tied to disclosures in late 2025; firms (Rosen, Pomerantz, Bernstein Liebhard, Hagens Berman, Faruqi, Gross, Berger Montague, Holzer & others) are soliciting investors and reminding of the April 13 lead‑plaintiff deadline — this increases litigation risk and potential headline volatility. Read More. Read More.
• Negative Sentiment: At least one public update highlights alleged FDA rebukes and accusations of “distorted” data related to uniQure programs — these regulatory and data‑integrity concerns are material for biotech valuations and may prolong uncertainty around clinical/regulatory timelines. Read More.
• Negative Sentiment: Barclays cut its price target from $31 to $25 and kept an “equal weight” (hold) rating — a downward revision from a major analyst can weigh on sentiment even though the new target still implies upside versus current levels. Read More.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.